Unknown

Dataset Information

0

Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment.


ABSTRACT: SARS-CoV-2 infection during pregnancy is associated with severe COVID-19 and adverse fetal outcomes, but the underlying mechanisms remain poorly understood. Moreover, clinical studies assessing therapeutics against SARS-CoV-2 in pregnancy are limited. To address these gaps, we developed a mouse model of SARS-CoV-2 infection during pregnancy. Outbred CD1 mice were infected at E6, E10, or E16 with a mouse-adapted SARS-CoV-2 (maSCV2) virus. Outcomes were gestational age-dependent, with greater morbidity, reduced antiviral immunity, greater viral titers, and impaired fetal growth and neurodevelopment occurring with infection at E16 (third trimester equivalent) than with infection at either E6 (first trimester equivalent) or E10 (second trimester equivalent). To assess the efficacy of ritonavir-boosted nirmatrelvir, which is recommended for individuals who are pregnant with COVID-19, we treated E16-infected dams with mouse-equivalent doses of nirmatrelvir and ritonavir. Treatment reduced pulmonary viral titers, decreased maternal morbidity, and prevented offspring growth restriction and neurodevelopmental impairments. Our results highlight that severe COVID-19 during pregnancy and fetal growth restriction is associated with heightened virus replication in maternal lungs. Ritonavir-boosted nirmatrelvir mitigated maternal morbidity along with fetal growth and neurodevelopment restriction after SARS-CoV-2 infection. These findings prompt the need for further consideration of pregnancy in preclinical and clinical studies of therapeutics against viral infections.

SUBMITTER: Creisher PS 

PROVIDER: S-EPMC10575736 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment.

Creisher Patrick S PS   Perry Jamie L JL   Zhong Weizhi W   Lei Jun J   Mulka Kathleen R KR   Ryan W Hurley WH   Zhou Ruifeng R   Akin Elgin H EH   Liu Anguo A   Mitzner Wayne W   Burd Irina I   Pekosz Andrew A   Klein Sabra L SL  

The Journal of clinical investigation 20231016 20


SARS-CoV-2 infection during pregnancy is associated with severe COVID-19 and adverse fetal outcomes, but the underlying mechanisms remain poorly understood. Moreover, clinical studies assessing therapeutics against SARS-CoV-2 in pregnancy are limited. To address these gaps, we developed a mouse model of SARS-CoV-2 infection during pregnancy. Outbred CD1 mice were infected at E6, E10, or E16 with a mouse-adapted SARS-CoV-2 (maSCV2) virus. Outcomes were gestational age-dependent, with greater morb  ...[more]

Similar Datasets

| S-SCDT-10_15252-EMMM_202317580 | biostudies-other
| S-EPMC9970919 | biostudies-literature
2021-11-11 | GSE185557 | GEO
| S-EPMC7264541 | biostudies-literature
| S-SCDT-EMBOJ-2020-106267 | biostudies-other
| S-EPMC4109496 | biostudies-literature
| S-EPMC8020997 | biostudies-literature
| S-EPMC8766450 | biostudies-literature
2013-10-08 | E-GEOD-41438 | biostudies-arrayexpress
| S-EPMC8305278 | biostudies-literature